NCT05567783Phase 2Terminated

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Study sponsor: Vir Biotechnology, Inc. · VIR

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-05-05Actual

Enrollment · participants2977Actual

Source updated2024-09-19Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Influenza A

Treatments or interventions studied

VIR-2482 (450 mg)Biological
VIR-2482 (1200 mg)Biological
PlaceboBiological

Primary outcomes · main study measures

Read the study measures

measure: Percentage of Participants With Protocol-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR]); description: Protocol-defined ILI with confirmed influenza A defined as RT-PCR confirmed influenza A with at least one respiratory symptom and at least one systemic symptom; timeFrame: Up to 24 Weeks; measure: Number of Participants With Adverse Events (AEs); timeFrame: Up to 26 Weeks; measure: Number of Participants With Serious Adverse Events (SAEs); timeFrame: Up to 26 Weeks; measure: Number of Participants With Adverse Events of Special Interest (AESI); description: AESI is anaphylaxis per MedDRA anaphylaxis algorithmic SMQ; timeFrame: Up to 26 Weeks; measure: Number of Participants With Vital Sign Abnormalities; description: Defined as a graded abnormality in systolic blood pressure, diastolic blood pressure, pulse, respiratory rate, or oral temperature as per the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials at any time on/after receipt of study intervention.; timeFrame: Up to 26 Weeks; measure: Number of Participants With Clinical Laboratory Abnormalities; description: Defined as graded abnormality in chemistry, hematology, liver function, or urinalysis clinical laboratory values as per the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials at any time on/after receipt of study intervention.; timeFrame: Up to 26 Weeks; measure: Number of Participants With Solicited Injection Site Reactions; description: Injection site reactions from the study intervention diary card; timeFrame: Up to Day 7 following study intervention administration; measure: Number of Participants With Solicited Systemic Reactions; description: Systemic reactions from the study intervention diary card; timeFrame: Up to Day 7 following study intervention administration

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history